期刊文献+

奈达铂联合雷替曲塞治疗晚期喉咽癌17例分析 被引量:3

下载PDF
导出
摘要 目的:观察奈达铂联合雷替曲塞治疗晚期喉咽癌的疗效及毒副反应。方法奈达铂80~100 mg/m2,加雷替曲塞3mg/m2静脉注射每3~4周重复,至少2个周期评价疗效。结果17例患者的有效率(CR+PR)为70.6%,且不良反应轻。主要表现为血液毒性和胃肠道反应。结论奈达铂联合雷替曲塞治疗晚期喉咽癌疗效高,毒性轻,可耐受且临床应用方便,值得推广。
作者 迟洪亮
出处 《中国医药指南》 2014年第19期199-200,共2页 Guide of China Medicine
  • 相关文献

参考文献2

二级参考文献9

  • 1祁永发,屠规益,唐平章.颈段食管癌外科手术及综合治疗初探[J].中华外科杂志,1995,33(3):176-178. 被引量:22
  • 2Taguchi T, Wakui A, Nabeya K, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group [J]. Gan To Kagaku Ryoho, 1992,19(4):483-488.
  • 3Inuyama Y, Miyake H, Horiuchi M, et al. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers [J]. Gan To Kagaku Ryoho, 1992,19(6): 871-877.
  • 4Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients[J]. J Clin Oncol, 1994,12:360-367.
  • 5Furuse K, Fukuoka M, Asamoto H, et al. A randomized comparative study of 254-S plus vindesine(VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC) [J]. Gan To Kagaku Ryoho,1992,19(7):1019-1026.
  • 6Fukuda M, Shinkai T, Eguchi K, et al. Phase II study of (glycolate-O,O′ ) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer [J]. Cancer Chemother Pharmacol,1990,26(6):393-396.
  • 7Yoshioka T, Gamoh M, Shineha R, et al. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers [J]. Intern Med, 1999, 38(11): 844-848.
  • 8徐瑞华,管忠震.硫酸长春地辛Ⅲ期临床试验总结[J].癌症,1998,17(3):197-200. 被引量:32
  • 9徐瑞华,姜文奇,刘冬耕,滕小玉,管忠震.VIP与MVP方案治疗非小细胞肺癌的对照研究[J].癌症,1999,18(6):711-713. 被引量:12

共引文献140

同被引文献31

  • 1岳顺,张大红,周磊磊.雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效[J].肿瘤防治研究,2014,41(2):160-162. 被引量:21
  • 2Hagner N, Joerger M. Cancer chemotherapy:targeting folic acid synthesis[ J ]. Cancer Manag Res ,2010,19 (5) :293 - 301.
  • 3Van CE, Oliveirea J. ESMO Guidelines Working Group. Ad- vanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow - up [ J ]. Ann Oncol, 2009,20(4) :61 -65.
  • 4Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed- based first -line chemotherapy in advanced colorectal cancer [ J ]. Anticancer Drugs, 2014, 25 ( 10 ) : 1122 - 1128.
  • 5Liu Y, Wu W, Hang W, et al. Rahitrexed - based chemo- therapy for advanced colorectal cancer[ J]. Clin Res Hepa- tol Gastroenterol,2014,38 (2) : 219 - 225.
  • 6Bozkurt O, Karaca H, Ciltas A, et al. Efficacy and safety of rahitrexed combinations with uracil - tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of anatolian society of medical oncology (ASMO) [ J ]. Asian Pac J Cancer Prey,2014,15 (4) : 1845 - 1849.
  • 7王佳蕾,李进,刘天舒,等.雷替曲塞或5-FU/CF联合奥沙利铂治疗局部晚期或复发转移性结直肠癌多中心、随机、对照Ⅲ期临床试验[C].北京:第十届全国临床肿瘤学大会暨2007年CSCO学术年会中国临床肿瘤学教育专辑,2007:335-340.
  • 8Kim GP, Sargent D J, Mahoney MR, et al. Phase III noninfe- riority trial comparing irinotecan with oxaliplatin, fluoroura-cil,and leucovorin in patients with advanced colorectal car- cinoma previously treated with fluorouracil: N9841 [ J ]. J Clin Oneo1,2009,27(17) :2848 - 2854.
  • 9Shen J, Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomark- ers for raltitrexed sensitivity in gastric cancer [ J ]. Int J Cancer,2012,131 ( 6 ) :938 - 945.
  • 10Wei J, Costa C, Ding Y, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second - line docetaxel in advanced gastric cancer [ J ]. J Natl Cancer Inst ,2011,103 (20) : 1552 - 1556.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部